Trials: China's new COVID drugs showing good results︱国内新研发新冠药物功效良好

Drug researchers in China are making progress on developing therapies to treat COVID-19 with several antibody drugs, which neutralize the virus, emerging as promising candidates in clinical trials.

国内药物研究人员在开发用数种抗体药物治疗新冠病毒的方法上成效愈显。此内不少药物能够中和新冠病毒，有望成为临床候选药品。

Sunney Xie, director of the Beijing Advanced Innovation Center for Genomics at Peking University and a world-renowned biochemist, said his team has discovered a "full-spectrum neutralizing antibody" that has tackled all known emerging variants in laboratory experiments.

北京大学基因组学高级创新中心主任、世界知名生化学家谢晓亮接受采访，表示他的团队发现了一种“全谱”中和抗体，在实验室中已经成功应对所有已知新冠病毒变异株。

The antibody, known as DXP-604, is so potent that it will likely treat any mutations, he said at an academic conference in Shanghai last week.

上周，谢晓亮在上海召开的学术会议上告诉记者，这种被称为DXP-604的抗体非常有效，或许能有效应对新冠病毒的所有异变。

Xie added that a new drug based on DXP-604 has demonstrated good efficacy in Phase 2 clinical trials. As of Nov 2, the medication had been administered to 14 patients with COVID-19 at Beijing Ditan Hospital through the compassionate use program, which expands access to experimental drugs for critical patients.

他补充称，团队研发的新冠中和抗体DXP-604的二期临床试验疗效良好，并且已经被批准在北京地坛医院作为同情用药紧急治疗使用，扩大危重患者获得实验药物的机会。截至11月2日，已有14名患者接受治疗，目前正在等待临床试验的结果。

In the meantime, Brii Biosciences announced recently that it has filed an application for emergency use authorization with the US Food and Drug Administration for its therapy that combines two neutralizing antibodies, BRII-196 and BRII-198.

上海腾盛博药医药技术有限公司也宣布，公司已经向 FDA递交新冠中和抗体BRII-196/BRII-198联合疗法的紧急使用授权申请。

Brii Biosciences is a multinational pharmaceutical company based in China and the United States. It codeveloped the drug with Tsinghua University and the Third People's Hospital of Shenzhen.

腾盛博药医药技术公司是一家中美合资跨国制药公司，该公司与清华大学和深圳第三人民医院共同研发了该药物。

The company said results from Phase 3 clinical trials overseas have shown that the medication can cut the risk of hospitalization and death of COVID-19 patients by 78 percent. Many participants enrolled in the trials were infected with the highly transmissible Delta variant.

公司表示，海外三期临床试验结果表明，在多数参试者均感染高度可传播的Delta变体的情况下，BRII-196/BRII-198联合疗法将患者入院与死亡的风险降低了78%。

Hong Zhi, chairman and CEO of the company, said that while vaccination remains the primary weapon against the novel coronavirus, antibody therapies can trigger immune responses more rapidly and are the most suitable treatment for close contacts of infected people and those who have already contracted the virus, but have not begunto show symptoms.

腾盛博药的董事长兼首席执行官洪志指出，疫苗接种虽仍是对抗新型冠状病毒的主要武器，然而抗体疗法可以更快触发免疫应答，是最适合密切接触者和无症状感染者的治疗方法。

Brii Biosciences said in a statement on Friday it will offer the drug to Heilongjiang and Qinghai provinces for free. Both provinces are coping with local outbreaks.

周五，腾盛博药发表声明，将向目前疫情未平的黑龙江省与青海省免费提供该药物。

Since June, nearly 700 patients in China had received the drug. Preliminary feedback from frontline medical workers suggests that the drug is safe and shows good antiviral effects on emerging variants, the statement said.

声明指出，今年六月以来，中国已有近700名患者用过该药，而来自一线医务人员的初步反馈表明，药物安全，且对新出现的变种毒株有较好的抗病毒效果。

"Vaccines and antibody therapies are two weapons that complement each other," said Zhang Linqi, a professor at Tsinghua University's School of Medicine.

清华大学医学院教授张林琦介绍称：“疫苗和抗体疗法相辅相成。”

During an interview with ThePaper, a news outlet, he said highly effective and broad-spectrum antibodies can induce effects very quickly and will mainly benefit people exhibiting mild and moderate symptoms or who are at risk of developing severe symptoms.

在接受澎湃新闻采访时，他表示高效广谱抗体生效迅速，适用于轻症、中症以及可能发展为重症的患者。

neutralize

英 [ˈnjuːtrəlaɪz]；美[ˈnuːtrəlaɪz]

vt. （使）无效；中和；（使）中立

spectrum

英 [ˈspektrəm]；美[ˈspektrəm]

n. （光、波、声、频）谱；范围；各层次

compassionate

英 [kəmˈpæʃənət]；美[kəmˈpæʃənət]

adj.有同情心的；怜悯的

v. 同情；怜悯

transmissible

英 [træns'mɪsəbl]；美[træns'mɪsəbəl]

adj. 可转移的；可传播的

国内新研发新冠药物 ︱Trials: China's new COVID drugs showing good results 03:23 Share

China Daily Podcast

Shownotes Transcript

国内新研发新冠药物︱Trials: China's new COVID drugs showing good results